Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis

详细信息    查看全文

• 作者：Claudio Luchini ; Nicola Veronese ; Shinichi Yachida ; Liang Cheng ; Alessia Nottegar ; Brendon Stubbs ; Marco Solmi ; Paola Capelli ; Antonio Pea ; Mattia Barbareschi ; Matteo Fassan ; Laura D Wood and Aldo Scarpa
• 刊名：Genes, Chromosomes and Cancer
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：55
• 期：10
• 页码：741-749
• 全文大小：178K
• ISSN：1098-2264

文摘

Biallelic inactivation of the tumor suppressor gene BRCA1-associated protein 1 (BAP1) has been demonstrated in several cancers, but its prognostic role has not been completely explained. We aimed to investigate the risk associated with loss of BAP1 (BAP1-) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS were searched from database inception until 09/15/2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of BAP1 (BAP1+) vs. BAP1- were included. Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time-dependent risk related to BAP1- adjusted for potential confounders. From 261 hits, 12 studies (including 13 cohorts) with 3,447 participants (BAP1-: n = 697; BAP1+: n = 2,750), with a median follow-up over 60 months, were meta-analyzed. Compared to BAP1+, BAP1- significantly increased all-cause mortality, cancer-specific mortality and risk of recurrence in all the tumor types analyzed, except for mesothelioma, in which the presence of BAP1 mutations correlates with a better prognosis. Furthermore, we demonstrated that BAP1 mutated colorectal and renal carcinomas are associated with high-tumor grading (P < 0.0001), and that BAP1 mutated is more common in women than in men (P < 0.0001). In conclusion, on the basis of our meta-analysis, we have demonstrated a peculiar role of BAP1 in influencing the prognosis in cancer. Thus, BAP1 could be considered as an important potential target for personalized medicine.